May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Efficacy and Adverse Effects of Ciclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis
Author Affiliations & Notes
  • C. Tappeiner
    Dept. of Ophthalmology, at St. Franziskus Hospital, Muenster, Germany
    Dept. of Ophthalmology, Inselspital, University, Bern, Switzerland
  • C. Heinz
    Dept. of Ophthalmology, at St. Franziskus Hospital, Muenster, Germany
  • H. Michels
    Dept. of Pediatric Rheumatology, Garmisch-Partenkirchen, Germany
  • G. Ganser
    Dept. of Pediatric Rheumatolgy, Sendenhorst, Germany
  • A. Heiligenhaus
    Dept. of Ophthalmology, at St. Franziskus Hospital, Muenster, Germany
  • Footnotes
    Commercial Relationships C. Tappeiner, None; C. Heinz, None; H. Michels, None; G. Ganser, None; A. Heiligenhaus, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3913. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Tappeiner, C. Heinz, H. Michels, G. Ganser, A. Heiligenhaus; Efficacy and Adverse Effects of Ciclosporine A in the Treatment of Chronic Anterior Uveitis in Patients With Juvenile Idiopathic Arthritis. Invest. Ophthalmol. Vis. Sci. 2007;48(13):3913.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Juvenile idiopathic arthritis (JIA) is often associated with chronic anterior uveitis (CAU). Severe inflammation or the development of vision-threatening complications may indicate immunosuppressive therapy. In this study, the experience with ciclosporine A (CsA) as mono- or combination-therapy and its efficacy in methotrexate-nonresponders was analyzed.

Methods:: Multicenter, retrospective analysis of the clinical observations with CsA in JIA children with CAU.

Results:: Eighty-two JIA children (girls n=60, oligoarthritis n=65, RF-negative polyarthritis n=13, psoriatic arthritis n=1, other arthritis n=3) suffering from unilateral (n=55) or bilateral CAU were treated with systemic CsA (mean dosage 2.9 mg/kg, mean follow up 3.9 years). CsA was indicated by persistently active CAU despite of topical or systemic corticosteroids, etanercept, azathioprine or methotrexate. Uveitis quiescence was achieved with CsA as monotherapy in 8 out of 20 patients (40%), and in 33 out of 70 patients (47.1%) with CsA in combination with MTX (n=16), azathioprine (n=11) or others (n=6). With CsA, a reduction ≥50% of topical steroids (n=38), systemic immunosuppressives or steroids (n=21) was possible. Preexisting CME did not resolve on CsA in any of the patients. In 9 patients (11%), CsA was discontinued because of systemic hypertension (n=1), creatinine elevation (n=3), or other adverse effects (n=5).

Conclusions:: The observations suggest that CsA as monotherapy, and in MTX nonresponders as combination therapy has limited efficacy for the treatment of JIA-associated CAU.

Clinical Trial:: www.clinicaltrials.gov NCT00404482

Keywords: autoimmune disease • clinical (human) or epidemiologic studies: outcomes/complications • cyclosporine 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×